- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 317/24 - Radicals substituted by singly bound oxygen or sulfur atoms esterified
Patent holdings for IPC class C07D 317/24
Total number of patents in this class: 85
10-year publication summary
|
8
|
7
|
7
|
3
|
1
|
2
|
6
|
9
|
5
|
1
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| JSR Corporation | 2527 |
8 |
| NanoVation Therapeutics Inc. | 63 |
7 |
| Segetis, Inc. | 39 |
4 |
| Eisai R&D Management Co., Ltd. | 1232 |
4 |
| BASF SE | 20940 |
3 |
| AstraZeneca AB | 2892 |
3 |
| Sumitomo Chemical Company, Limited | 9043 |
3 |
| SCF Pharma Inc. | 30 |
3 |
| Veiled Therapeutics, LLC | 11 |
3 |
| Niche Biopharmaceuticals LLC | 4 |
3 |
| Novartis AG | 10744 |
2 |
| The Regents of the University of California | 19961 |
2 |
| Firmenich SA | 1686 |
2 |
| Gfbiochemicals Limited | 49 |
2 |
| Institut Univ. de Ciencia i Tecnologia, S.A. | 22 |
2 |
| NOK Corporation | 2222 |
2 |
| Promega Corporation | 574 |
2 |
| F. Hoffmann-La Roche AG | 7947 |
1 |
| LG Chem, Ltd. | 17635 |
1 |
| AstraZeneca UK Limited | 637 |
1 |
| Other owners | 27 |